Table 1 Clinicopathological features of patients with HBV-related hepatocellular carcinoma
From: Prognostic factors in patients with HBV-related hepatocellular carcinoma following hepatic resection
Characteristic | Value |
|---|---|
Gender, n (%) (total cohort n = 217) | |
 male | 100 (46.08) |
 female | 117 (53.92) |
Age (years), mean ± sd | 56.12 (9.78) |
HBsAg, n (%) | |
 negative | 16 (7.37) |
 positive | 201 (92.62) |
HBeAg, n (%), n = 119 | |
 negative | 85 (71.43) |
 positive | 34 (28.57) |
HBV DNA, n (%), n = 103 | |
 negative | 41 (39.81) |
 positive | 62 (60.19) |
HCV, n (%) | |
 no | 210 (96.77) |
 yes | 7 (3.23) |
Platelets × 103 (mm3), median (range) | 190.5 (57, 568) |
AFP-pre (ng/mL), median (range), n = 185 | 16.8 (0.89, 82,392) |
AFP-post (ng/mL), median (range), n = 125 | 3.48 (0.83, 19,629) |
Tumor size (cm), median (range), n = 216 | 4.5 (0.5, 26.5) |
  < 5 | 120 (55.56) |
  ≥ 5 | 96 (44.44) |
Number of tumors, n (%) | |
 solitary | 166 (77.57) |
 multiple | 48 (22.43) |
Microvascular invasion, n (%) | |
 no | 170 (79.44) |
 yes | 44 (20.56) |
Stage, n (%) | |
 I | 138 (63.59) |
 II or higher | 79 (36.41) |
Resection margin, n (%), n = 185 | |
 free margin | 176 (95.14) |
 positive margin | 9 (4.86) |
Operation type, n (%) | |
 non-anatomical | 129 (59.45) |
 anatomical | 88 (40.55) |
Preoperative neoadjuvant, n (%), n = 164 | |
 no | 92 (56.10) |
 yes | 72 (43.90) |
Platelet-to-lymphocyte ratio, median (range), n = 203 | 101.8 (30.9, 432.8) |
Prognostic nutritional index, mean ± sd n = 206 | 95.18 (40.21) |
Neutrophil-to-lymphocyte ratio, median (range), n = 201 | 1.77 (0.33, 10.62) |
Antiviral treatment | |
 no | 65 (29.95) |
 yes | 152 (70.05) |
Antiviral drug, n (%) | |
 Adefovir | 7 (3.23) |
 Lamivudine | 125 (57.60) |
 Tenofovir | 44 (20.28) |
 Entecavir | 20 (9.22) |
Antiplatelet treatment (ASA + Clopidogrel) | |
 no | 199 (91.71) |
 yes | 18 (8.29) |
Recurrence, n (%) | |
 no | 113 (52.07) |
 yes | 104 (47.93) |
Follow-up time (months), median (range) | 36.33 (0.23, 149.07) |